Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC. In the phase 1/2 trial, daraxonrasib ...
MSK gastrointestinal medical oncologist Eileen O'Reilly, MD (left), led a very promising early phase clinical trial of the targeted RAS therapy daraxonrasib for people facing pancreatic cancer.
Add the following CSS to the header block of your HTML document. Then add the mark-up below to the body block of the same document. .videoWrapper { position: relative; padding-bottom: 56.25%; ...
ISLAMABAD: The Higher Education Commission (HEC) on Friday said it has initiated a project to revamp its degree attestation system by integrating cutting-edge blockchain technology. “This pivotal ...
PESHAWAR: Vice-chancellor Khyber Medical University Prof Dr Ziaul Haq has been appointed executive director of Higher Education Commission (HEC) Islamabad. Prof Ziaul Haq is not only the youngest ...